Form 4: Inhibrx Biosciences Director Jon Faiz Kayyem Increases Stake in Company

Director Jon Faiz Kayyem reports multiple purchases of Inhibrx Biosciences (INBX) common stock, increasing his indirect holdings through a family trust.

Summary

• Jon Faiz Kayyem, a director of Inhibrx Biosciences, has reported several transactions involving the purchase of common stock.
• These purchases were made indirectly through The Jon F. Kayyem and Paige Gates-Kayyem Family Trust.
• On May 31, 2024, the trust acquired 70,193 shares at a weighted average price of $16.14, increasing the trust's holdings to 876,268 shares.
• On June 3, 2024, two transactions occurred: the trust purchased 46,792 shares at $16.61 and 80,738 shares at $17.90, bringing the total to 1,003,798 shares.
• On June 4, 2024, the trust further increased its holdings by purchasing 65,337 shares at $17.44 and 23,726 shares at $18.24, resulting in a total of 1,092,861 shares held by the trust.
• The reported prices are weighted averages due to multiple transactions within specified price ranges.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's increased investment in the company, suggesting confidence in its future. However, it's important to consider the context and reasons behind the purchases.

Positives

• A director increasing their stake in the company could be interpreted positively by investors, signaling confidence in the company's future prospects.

Industry Context

Director's stock purchases are often viewed as a positive signal in the biotech industry, reflecting confidence in the company's pipeline and future prospects. This is especially relevant for companies like Inhibrx Biosciences, which are focused on developing novel therapies.

Comparison to Industry Standards

• Comparing Kayyem's purchases to similar insider transactions at comparable biotech firms like Amgen (AMGN) or Regeneron (REGN) could provide context.
• For example, if executives at Amgen or Regeneron made similar purchases, it would be viewed as a positive sign for the industry as a whole.
• However, without knowing the specific reasons behind Kayyem's purchases, it's difficult to draw definitive conclusions.

Stakeholder Impact

• Shareholders may view the director's stock purchases as a positive signal, potentially leading to increased investor confidence.
• Employees may also see this as a sign of stability and positive future prospects for the company.

Key Dates